REMD2.59, a fully competitive antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb), has a strong hypoglycemic effect in T1D and T2D rodents and nonhuman primates [9–11]. This evidence concerns the gene GCGR and type 1 diabetes mellitus.